Form 4: Disc Medicine CEO Granted 55,200 RSUs and 82,800 Options

Disc Medicine, Inc. CEO John D. Quisel was granted 55,200 restricted stock units and 82,800 stock options, effective February 10, 2026.

Summary

• John D. Quisel, Chief Executive Officer and Director of Disc Medicine, Inc. (IRON), was granted 55,200 shares of Common Stock in the form of Restricted Stock Units (RSUs).
• These RSUs represent a contingent right to receive one share of Common Stock per unit and will vest annually in four 25% installments, commencing on February 15, 2027, subject to continued service.
• Additionally, Mr. Quisel was granted stock options to purchase 82,800 shares of Common Stock with an exercise price of $74.75 per share.
• The stock options will vest in 48 equal monthly installments, commencing on March 10, 2026, also subject to continued service.
• The options have an expiration date of February 9, 2036.
• Following these transactions, Mr. Quisel beneficially owns 239,328 shares of Common Stock and 82,800 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for long-term alignment between executive leadership and shareholder interests, reflecting standard executive compensation practices designed to incentivize performance.

Positives

• The grant of restricted stock units and stock options to the CEO aligns management's long-term interests with those of shareholders, as the value of these awards is tied to the company's stock performance.
• The significant equity stake incentivizes the CEO to drive sustained growth and profitability for Disc Medicine, Inc.

Negatives

• The awards are subject to future vesting schedules, meaning the CEO does not immediately realize the full value of the grants.
• The exercise price of the stock options ($74.75) is a benchmark that the stock price must exceed for the options to be 'in the money' and provide a direct financial benefit upon exercise.

Future Outlook

The grants are structured with future vesting schedules, indicating a long-term incentive plan for the CEO, contingent on continued service through February 2027 for RSUs and March 2026 for options, extending through their respective vesting periods.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and motivate key executives by aligning their financial interests with the long-term performance of the company and its shareholders.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of CEO's interests with long-term company performance.
• Employees: No direct impact mentioned, but a stable, incentivized leadership can indirectly benefit overall company stability and direction.
• CEO (John D. Quisel): Receives significant long-term equity incentives, contingent on continued service and company performance.

Next Steps

• John D. Quisel's continued service to Disc Medicine, Inc. is required for the vesting of both the Restricted Stock Units and the stock options.

Key Dates

Recommendation

The grant of restricted stock units and stock options to the CEO aligns management's long-term interests with those of shareholders, which is generally a positive governance signal. However, this Form 4 filing alone does not provide sufficient operational or financial data to warrant a change in a broader investment thesis, thus a 'hold' recommendation is appropriate based solely on this information.

Keywords

Disc Medicine, IRON, John D. Quisel, CEO, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Insider Transaction, Equity Grant, Corporate Governance